Nisa Investment Advisors LLC Purchases 2,694 Shares of InMode Ltd. (NASDAQ:INMD)

Nisa Investment Advisors LLC increased its position in InMode Ltd. (NASDAQ:INMD) by 314.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,550 shares of the healthcare company’s stock after purchasing an additional 2,694 shares during the quarter. Nisa Investment Advisors LLC’s holdings in InMode were worth $60,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Allspring Global Investments Holdings LLC increased its position in shares of InMode by 9.9% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 7,645 shares of the healthcare company’s stock valued at $165,000 after buying an additional 691 shares in the last quarter. Hohimer Wealth Management LLC raised its position in shares of InMode by 6.5% during the first quarter. Hohimer Wealth Management LLC now owns 14,923 shares of the healthcare company’s stock worth $322,000 after purchasing an additional 906 shares during the period. Headlands Technologies LLC raised its position in shares of InMode by 118.2% during the first quarter. Headlands Technologies LLC now owns 1,916 shares of the healthcare company’s stock worth $41,000 after purchasing an additional 1,038 shares during the period. ProShare Advisors LLC lifted its holdings in shares of InMode by 8.5% during the 1st quarter. ProShare Advisors LLC now owns 13,920 shares of the healthcare company’s stock valued at $301,000 after purchasing an additional 1,094 shares in the last quarter. Finally, Cetera Advisors LLC grew its position in shares of InMode by 8.9% in the 1st quarter. Cetera Advisors LLC now owns 17,028 shares of the healthcare company’s stock valued at $368,000 after purchasing an additional 1,394 shares during the period. 68.04% of the stock is owned by institutional investors.

Analysts Set New Price Targets

INMD has been the topic of several research reports. Needham & Company LLC reaffirmed a “hold” rating on shares of InMode in a research report on Thursday, October 31st. Barclays cut their price target on InMode from $29.00 to $27.00 and set an “overweight” rating on the stock in a report on Monday, October 14th. Canaccord Genuity Group reduced their price objective on InMode from $21.00 to $16.00 and set a “hold” rating for the company in a research report on Friday, July 12th. BTIG Research assumed coverage on InMode in a research report on Thursday, October 17th. They issued a “buy” rating and a $25.00 target price on the stock. Finally, Jefferies Financial Group downgraded InMode from a “buy” rating to a “hold” rating and reduced their price target for the stock from $21.00 to $19.00 in a research report on Tuesday, July 23rd. Four equities research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average price target of $22.60.

InMode Stock Down 0.2 %

InMode stock opened at $19.23 on Friday. The company has a market capitalization of $1.61 billion, a PE ratio of 10.39 and a beta of 2.15. The firm’s fifty day moving average is $16.86 and its 200 day moving average is $17.37. InMode Ltd. has a 12-month low of $14.87 and a 12-month high of $26.80.

InMode Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.